Evidence map›Paper›PMID 39892987›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2025

NOSH-aspirin (NBS-1120) inhibits estrogen receptor-negative breast cancer in vitro and in vivo by modulating redox-sensitive signaling pathways.

Mitali Chattopadhyay, Niharika Nath, Ravinder Kodela, Shalaka Metkar, Sarin A Soyemi, Khosrow Kashfi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mitali ChattopadhyayDepartment of Molecular, Cellular, and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, New York.
Niharika NathDepartment of Biological and Chemical Sciences, New York Institute of Technology, New York, New York.
Ravinder KodelaDepartment of Molecular, Cellular, and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, New York.
Shalaka MetkarDepartment of Molecular, Cellular, and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, New York.
Sarin A SoyemiDepartment of Molecular, Cellular, and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, New York.
Khosrow KashfiDepartment of Molecular, Cellular, and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, New York; Graduate Program in Biology, City University of New York Graduate Center, New York, New York. Electronic address: kashfi@med.cuny.edu.

Funding

Research Center in Minority Institutions (RCMI) at City CollegeU54MD017979 · NIMHD · CITY COLLEGE OF NEW YORK · PI Maria F Lima · 2024 to 2026
$15.9M
NIMHD NIH HHS U54 MD017979
6 · The paper itself

Abstract

Estrogen receptor (ER)-negative breast cancers are known to be aggressive and unresponsive to antiestrogen therapy, and triple-negative breast cancers are associated with poor prognosis and metastasis. Thus, new targeted therapies are needed. Forkhead box M1 (FOXM1) is abundantly expressed in human cancers and implicated in protecting tumor cells from oxidative stress by reducing the levels of intracellular reactive oxygen species (ROS). Aspirin, a prototypical anticancer agent with deleterious side effects that has been modified to release nitric oxide and hydrogen sulfide is called nitric oxide-hydrogen sulfide-releasing aspirin (NOSH-aspirin, NOSH-ASA), generating a "safer" class of new anti-inflammatory agents. We evaluated NOSH-ASA against ER-negative breast cancer using cell lines and a xenograft mouse model. NOSH-ASA strongly inhibited growth of MDA-MB-231 and SKBR3 breast cancer cells with low IC

Indexed as

Antineoplastic AgentsAspirinBreast NeoplasmsReceptors, EstrogenSignal TransductionAnimalsApoptosisCell Line, TumorCell ProliferationFemaleForkhead Box Protein M1HumansMiceMice, NudeNitric OxideOxidation-ReductionAntineoplastic AgentsAspirinForkhead Box Protein M1Nitric OxideReactive Oxygen SpeciesReceptors, EstrogenBreast cancerEstrogen receptor-negative breast cancerForkhead box M1, nitric oxide, and hydrogen sulfideNitric oxide-hydrogen sulfide–releasing aspirinReactive oxygen species

Identifiers

PMID39892987
PMCPMC13095630

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.